Optomed plc

04/29/2024 | Press release | Distributed by Public on 04/29/2024 04:21

No updates on the Optomed Aurora AEYE FDA clearance process

English
Published: 2024-04-29 12:20:00 CEST

Optomed Oyj
Other information disclosed according to the rules of the Exchange

No updates on the Optomed Aurora AEYE FDA clearance process

Optomed Plc Stock Exchange Release 29 April 2024 at 13:20, Helsinki

No updates on the Optomed Aurora AEYE FDA clearance process

Optomed is together with its partner AEYE Health in the process of obtaining a clearance for the AI fundus camera Optomed Aurora AEYE.

At this stage, Optomed does not have any new information regarding the FDA clearance process. Optomed will update market as new information becomes available.


Optomed Plc



Further enquiries

Juho Himberg, CEO, [email protected]

Optomed in Brief

Optomed is a Finnish medical technology company and a leading manufacturer of handheld fundus cameras and screening software. Optomed combines handheld fundus cameras with software and artificial intelligence with the aim to transform the diagnostic process of various diseases, such as rapidly increasing diabetic retinopathy. Optomed has offices in Finland, the US and China and the company's products are sold via various sales channels in over 60 countries globally

www.optomed.com


This news release was distributed by Company News System, www.nasdaqomxnordic.com/news/marketnotices
To subscribe on regulatory news from this company, go to the subscription page